V
Vahakn B. Shahinian
Researcher at University of Michigan
Publications - 89
Citations - 2581
Vahakn B. Shahinian is an academic researcher from University of Michigan. The author has contributed to research in topics: Prostate cancer & Androgen deprivation therapy. The author has an hindex of 23, co-authored 89 publications receiving 2031 citations.
Papers
More filters
Journal ArticleDOI
Urologist Practice Structure and Quality of Prostate Cancer Care
Parth K. Modi,Phyllis Yan,Brent K. Hollenbeck,Samuel R. Kaufman,Tudor Borza,Ted A. Skolarus,Ted A. Skolarus,Florian R. Schroeck,Andrew M. Ryan,Vahakn B. Shahinian,Lindsey A. Herrel +10 more
TL;DR: This work examined 3 aspects of urologist practice structure that may affect quality of prostate cancer care, including practice size, ownership of an intensity modulated radiation, and the role of funding and stigma in practice structure.
Posted ContentDOI
Learning from the "tail end" of de-implementation: the case of chemical castration for localized prostate cancer.
Ted A. Skolarus,Jane Forman,Jordan B. Sparks,Tabitha Metreger,Sarah T. Hawley,Megan E.V. Caram,Lesly A. Dossett,Alan Paniagua-Cruz,Danil V. Makarov,John T. Leppert,John T. Leppert,Jeremy B. Shelton,Kristian D. Stensland,Brent K. Hollenbeck,Vahakn B. Shahinian,Anne E. Sales,Daniela Wittmann +16 more
TL;DR: Use of the TDF domains and the COM-B model enabled us to conceptualize provider behavior with respect to low-value ADT use and clarify possible areas for intervention to effect de-implementation of low- Value ADT prescribing in localized prostate cancer.
Journal ArticleDOI
Mp86-16 spillover effects of the hospital readmission reduction program on radical cystectomy readmissions
Matthew Lee,Brent K. Hollenbeck,Mary K. Oerline,Ted A. Skolarus,Bruce L. Jacobs,Rita Jen,Amy N. Luckenbaugh,Vahakn B. Shahinian,Tudor Borza +8 more
TL;DR: Hospitals that succeeded in reducing readmission following major joint surgery targeted by the HRRP did not have similar reductions in readmissions following radical cystectomy, suggesting that each surgical condition may require tailored interventions to prevent readmissions.
Journal ArticleDOI
Pd05-06 promotional payments to medical oncologists and urologists and prescriptions for abiraterone and enzalutamide
Lillian Y. Lai,Mary K. Oerline,Samuel R. Kaufman,Lindsey A. Herrel,Ted A. Skolarus,Stacie B. Dusetzina,Chad Ellimoottil,Vahakn B. Shahinian,Brent K. Hollenbeck,Megan E.V. Caram +9 more
TL;DR: The introduction of abiraterone and enzalutamide has allowed medical oncologists and urologists to manage patients with advanced prostate cancer with oral therapeutics with Oral therapeutics.
Journal ArticleDOI
Medicare Accountable Care Organizations and the Adoption of New Surgical Technology
Parth K. Modi,Samuel R. Kaufman,Megan Ev. Caram,Andrew M. Ryan,Vahakn B. Shahinian,Brent K. Hollenbeck +5 more
TL;DR: Despite ACO policy incentives to selectively adopt newer surgical technology, ACO participation was not associated with differences in rate of surgery or use of newer surgicaltechnology for 6 major surgical procedures.